#1 Clinical Trials Search in Europe

Dotatate

Dotatate is a promising compound being studied in clinical trials for its potential in imaging and treating neuroendocrine tumors (NETs) and other cancers expressing somatostatin receptors. This article explores how Dotatate, when combined with radioactive isotopes like Gallium-68 or Lutetium-177, is being used to improve diagnosis, staging, and treatment of these challenging cancers.

Table of Contents

What is DOTATATE?

DOTATATE is a specialized medical compound used in the diagnosis and treatment of certain types of cancers, particularly neuroendocrine tumors (NETs). It is often combined with radioactive elements like Gallium-68 (68Ga), Lutetium-177 (177Lu), or Yttrium-90 (90Y) to create imaging agents or therapeutic drugs[1][2].

DOTATATE has several variations and synonyms, including:

  • 68Ga-DOTATATE
  • 177Lu-DOTATATE (also known as Lutathera®)
  • 90Y-DOTATATE
  • 68Ga-HA-DOTATATE (high-affinity DOTATATE)
  • (68Ga-DOTA-0-Tyr3)-Octreotate

How DOTATATE Works

DOTATATE works by targeting somatostatin receptors (SSTRs), which are proteins found on the surface of many neuroendocrine tumor cells. When combined with radioactive elements, DOTATATE can either help detect these tumors through imaging or deliver targeted radiation therapy to the cancer cells[1].

The mechanism of action involves:

  1. Binding to somatostatin receptors on tumor cells
  2. Delivering radioactive particles to these cells
  3. Enabling visualization of tumors (for diagnostic purposes) or destroying cancer cells (for therapeutic purposes)

Conditions Treated with DOTATATE

DOTATATE is primarily used for neuroendocrine tumors, but it may also be helpful in other conditions. The main conditions treated or diagnosed using DOTATATE include[1][3]:

  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): These are tumors that form in the digestive system, including the stomach, intestines, and pancreas.
  • Bronchopulmonary carcinoids: These are a type of NET that occurs in the lungs.
  • Pheochromocytomas and paragangliomas: These are rare tumors that develop in certain glands in the body.
  • Medullary thyroid cancer: A type of thyroid cancer that begins in specific thyroid cells called C cells.
  • Other cancers expressing somatostatin receptors: Some other types of cancers may also have these receptors and could potentially be treated or diagnosed using DOTATATE.

Diagnostic Use of DOTATATE

One of the primary uses of DOTATATE is in diagnostic imaging, particularly with PET/CT (Positron Emission Tomography/Computed Tomography) scans. This imaging technique helps doctors[1][4]:

  • Detect and locate neuroendocrine tumors
  • Determine the extent of the disease (staging)
  • Monitor response to treatment
  • Plan appropriate treatments

68Ga-DOTATATE PET/CT has shown superior accuracy compared to traditional imaging methods like CT scans or older nuclear medicine techniques[4].

Therapeutic Use of DOTATATE

DOTATATE is also used as a treatment for certain neuroendocrine tumors in a procedure called Peptide Receptor Radionuclide Therapy (PRRT). In this treatment[2][5]:

  • DOTATATE is combined with therapeutic radioactive elements like Lutetium-177 or Yttrium-90.
  • The compound is administered intravenously (through a vein).
  • It targets and delivers radiation directly to tumor cells, potentially shrinking tumors and improving symptoms.

PRRT with DOTATATE is typically used for patients with advanced or metastatic neuroendocrine tumors that cannot be surgically removed[2].

Safety and Side Effects

While DOTATATE is generally considered safe, it can cause some side effects. These may include[6]:

  • Changes in blood cell counts
  • Alterations in kidney or liver function tests
  • Nausea or vomiting
  • Fatigue

When used for imaging, the side effects are typically minimal due to the very small amounts of radioactive material used. For therapeutic use, side effects may be more pronounced but are generally manageable under medical supervision[6].

Ongoing Research and Future Directions

Research on DOTATATE is ongoing, with several clinical trials exploring its potential in various areas[7][8]:

  • Optimizing dosages for both diagnostic and therapeutic use
  • Exploring its potential in other types of cancers, such as breast cancer
  • Investigating the relationship between DOTATATE uptake and tumor characteristics
  • Comparing different formulations of DOTATATE (e.g., 68Ga-DOTATATE vs. 64Cu-DOTATATE)

These ongoing studies aim to further improve the diagnosis and treatment of neuroendocrine tumors and potentially expand the use of DOTATATE to other cancer types[7].

Aspect Details
Primary Uses of Dotatate 1. Diagnostic imaging (Ga-68 DOTATATE PET/CT)
2. Targeted radiation therapy (Lu-177 DOTATATE/Lutathera)
Cancer Types Studied Neuroendocrine tumors, carcinoid tumors, medullary thyroid cancer, breast cancer, and other somatostatin receptor-positive cancers
Imaging Applications Tumor detection, staging, treatment planning, monitoring treatment response
Treatment Applications Targeted radiation therapy for inoperable or metastatic neuroendocrine tumors
Key Outcome Measures Progression-free survival, overall survival, tumor response rates, changes in tumor markers
Safety Considerations Monitoring for adverse events, changes in blood cell counts, liver and kidney function
Potential Advantages Improved tumor detection, more accurate staging, personalized treatment planning, targeted therapy for somatostatin receptor-positive cancers

FAQ

  • What is Dotatate and how is it used in clinical trials? Dotatate is a somatostatin analog that, when combined with radioactive isotopes like Gallium-68 or Lutetium-177, can be used for imaging (PET/CT scans) or treatment of neuroendocrine tumors. In clinical trials, it's being studied to improve diagnosis, staging, and treatment of cancers expressing somatostatin receptors.
  • What types of cancers are being studied with Dotatate? Clinical trials are investigating Dotatate for various cancers, including neuroendocrine tumors, carcinoid tumors, medullary thyroid cancer, breast cancer, and other cancers that express somatostatin receptors.
  • How does Ga-68 DOTATATE PET/CT imaging work? Ga-68 DOTATATE is injected into the patient and binds to somatostatin receptors on tumor cells. A PET/CT scanner then detects the radiation emitted by the Ga-68, creating detailed images that can show the location and extent of tumors expressing these receptors.
  • What is Lu-177 DOTATATE (Lutathera) and how is it used in treatment? Lu-177 DOTATATE, also known as Lutathera, is a radioactive drug used for treating certain types of neuroendocrine tumors. It combines the targeting ability of Dotatate with the cell-killing radiation of Lutetium-177, delivering targeted radiation therapy to tumor cells expressing somatostatin receptors.
  • What are some potential benefits of using Dotatate in cancer management? Dotatate-based imaging and treatments may offer improved tumor detection, more accurate staging, better treatment planning, and potentially more effective targeted therapy for patients with somatostatin receptor-positive cancers. Clinical trials aim to determine if these approaches can lead to better outcomes compared to conventional methods.

Ongoing Clinical Trials on Dotatate

  • Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of Lutetium-177 and Yttrium-90 DOTATATE combination therapy for patients with inoperable gastrointestinal neuroendocrine tumors

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study of Lutetium (177Lu) Oxodotreotide, Carboplatin, Etoposide, and Atezolizumab in Newly Diagnosed Extensive Stage Small Cell Lung Cancer Patients

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +2

Glossary

  • Neuroendocrine tumor (NET): A type of cancer that begins in specialized cells called neuroendocrine cells, which have traits of both nerve cells and hormone-producing cells.
  • Somatostatin receptor (SSTR): A protein found on the surface of certain cells, particularly abundant in many neuroendocrine tumors, that binds to the hormone somatostatin or similar molecules.
  • PET/CT: Positron Emission Tomography/Computed Tomography, an imaging technique that combines functional (PET) and anatomical (CT) information to detect and localize abnormalities in the body.
  • Ga-68 DOTATATE: A radioactive tracer used in PET/CT imaging that combines the somatostatin analog DOTATATE with the radioactive isotope Gallium-68.
  • Lu-177 DOTATATE (Lutathera): A radioactive drug that combines DOTATATE with Lutetium-177, used for targeted radiation therapy of certain neuroendocrine tumors.
  • Krenning Score: A scale used to assess the uptake of somatostatin receptor-targeting tracers in tumors compared to normal tissues.
  • SUV (Standardized Uptake Value): A measure of the concentration of radioactive tracer in a specific area of the body, used to quantify uptake in PET imaging.
  • RECIST criteria: Response Evaluation Criteria In Solid Tumors, a set of rules used to assess cancer patients' response to treatment in clinical trials.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing or worsening.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients diagnosed with a disease are still alive.

References

  1. https://clinicaltrials.gov/study/NCT04041882
  2. https://clinicaltrials.gov/study/NCT04029428
  3. https://clinicaltrials.gov/study/NCT02174679
  4. https://clinicaltrials.gov/study/NCT01873248
  5. https://clinicaltrials.gov/study/NCT02489604
  6. https://clinicaltrials.gov/study/NCT03145857
  7. https://clinicaltrials.gov/study/NCT05880394
  8. https://clinicaltrials.gov/study/NCT02840149